ClariTrial | Search Clinical Trials

Explore/atopic dermatitis

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

234 results for “atopic dermatitis” · Recruiting

Page 1 of 16

Recruiting

Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients

N/AEczemaPsoriasisUrticaria

Digital psychotherapeutic interventionHealthy365

National University Hospital, Singapore690 participants1 site · SingaporeCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis

N/AAtopic Dermatitis (Eczema)

blood sampling

Zhongda Hospital80 participants1 site · ChinaCompletes Jun 2026

Compare CT.gov Full analysis →

Recruiting

Drug Survival of Target Therapies in Atopic Dermatitis

N/AAtopic Dermatitis

target therapies (biological drug, small molecules)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS1,167 participants1 site · ItalyCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

Phase 2Atopic DermatitisAtopicDermatitis

CamoteskimabPlacebo

Apollo Therapeutics Ltd280 participants85 sites · United States, Bulgaria, CanadaCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.

Phase 4Lichen Plano-Pilaris

Nemolizumab

The Skin Center Dermatology Group10 participants1 site · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Prebiotic Effects of Mulberry Fruit in Children and Adolescents With Atopic Dermatitis

N/AAtopic Dermatitis (Eczema)Atopic Dermatitis, Probiotics

Mulberry fruit juiceMometasone furoate 0.1% cream

Taipei Medical University Shuang Ho Hospital120 participants2 sites · TaiwanCompletes Feb 2026

Compare CT.gov Full analysis →

Recruiting

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Phase 2Atopic Dermatitis

APG777APG777APG777

Apogee Therapeutics, Inc.350 participants68 sites · United States, Canada, CzechiaCompletes Dec 2029

Compare CT.gov Full analysis →

Recruiting

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

Phase 1Atopic Dermatitis (AD)

Onabotulinum Toxin Type A - Phase 1bOnabotulinum Toxin Type A - Phase 2

Daniel Kaplan8 participants2 sites · United StatesCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Prospective Longitudinal Observational Research in Atopic Dermatitis

N/AAtopic DermatitisAsthmaAtopic Dermatitis and Related Conditions

University of Zurich1,000 participants1 site · SwitzerlandCompletes Mar 2031

Compare CT.gov Full analysis →

Recruiting

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Phase 3Atopic Dermatitis

Abrocitinib

Pfizer500 participants38 sites · United States, China, GermanyCompletes Feb 2032

Compare CT.gov Full analysis →

Recruiting

Mind and Skin - the Neurocutaneous Axis in Atopic Eczema

N/AAtopic Dermatitis

MethotrexateDupilumab

King's College London90 participants1 site · United KingdomCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

N/AAtopic Dermatitis

Abrocitinib

Pfizer400 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

Phase 2Atopic DermatitisAtopic Dermatitis EczemaEczema

SoquelitinibPlacebo

Corvus Pharmaceuticals, Inc.200 participants1 site · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118

Phase 1Psoriasis

HS-20118HS-20118 placebo

Jiangsu Hansoh Pharmaceutical Co., Ltd.132 participants9 sites · United States, New ZealandCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

A Trial of Three- and Seven-days Insulin Infusions Set

N/AType 1 Diabetes

Mio Advanced infusions setNovorapidExtended wear insulin infusion (EWIS)+1 more

Steno Diabetes Center Copenhagen80 participants1 site · DenmarkCompletes Dec 2026

Compare CT.gov Full analysis →

1–15 of 234

Explore/atopic dermatitis

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

234 results for “atopic dermatitis” · Recruiting

Page 1 of 16

Recruiting

Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients

N/AEczemaPsoriasisUrticaria

Digital psychotherapeutic interventionHealthy365

National University Hospital, Singapore690 participants1 site · SingaporeCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis

N/AAtopic Dermatitis (Eczema)

blood sampling

Zhongda Hospital80 participants1 site · ChinaCompletes Jun 2026

Compare CT.gov Full analysis →

Recruiting

Drug Survival of Target Therapies in Atopic Dermatitis

N/AAtopic Dermatitis

target therapies (biological drug, small molecules)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS1,167 participants1 site · ItalyCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

Phase 2Atopic DermatitisAtopicDermatitis

CamoteskimabPlacebo

Apollo Therapeutics Ltd280 participants85 sites · United States, Bulgaria, CanadaCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.

Phase 4Lichen Plano-Pilaris

Nemolizumab

The Skin Center Dermatology Group10 participants1 site · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Prebiotic Effects of Mulberry Fruit in Children and Adolescents With Atopic Dermatitis

N/AAtopic Dermatitis (Eczema)Atopic Dermatitis, Probiotics

Mulberry fruit juiceMometasone furoate 0.1% cream

Taipei Medical University Shuang Ho Hospital120 participants2 sites · TaiwanCompletes Feb 2026

Compare CT.gov Full analysis →

Recruiting

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Phase 2Atopic Dermatitis

APG777APG777APG777

Apogee Therapeutics, Inc.350 participants68 sites · United States, Canada, CzechiaCompletes Dec 2029

Compare CT.gov Full analysis →

Recruiting

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

Phase 1Atopic Dermatitis (AD)

Onabotulinum Toxin Type A - Phase 1bOnabotulinum Toxin Type A - Phase 2

Daniel Kaplan8 participants2 sites · United StatesCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Prospective Longitudinal Observational Research in Atopic Dermatitis

N/AAtopic DermatitisAsthmaAtopic Dermatitis and Related Conditions

University of Zurich1,000 participants1 site · SwitzerlandCompletes Mar 2031

Compare CT.gov Full analysis →

Recruiting

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Phase 3Atopic Dermatitis

Abrocitinib

Pfizer500 participants38 sites · United States, China, GermanyCompletes Feb 2032

Compare CT.gov Full analysis →

Recruiting

Mind and Skin - the Neurocutaneous Axis in Atopic Eczema

N/AAtopic Dermatitis

MethotrexateDupilumab

King's College London90 participants1 site · United KingdomCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

N/AAtopic Dermatitis

Abrocitinib

Pfizer400 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

Phase 2Atopic DermatitisAtopic Dermatitis EczemaEczema

SoquelitinibPlacebo

Corvus Pharmaceuticals, Inc.200 participants1 site · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118

Phase 1Psoriasis

HS-20118HS-20118 placebo

Jiangsu Hansoh Pharmaceutical Co., Ltd.132 participants9 sites · United States, New ZealandCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

A Trial of Three- and Seven-days Insulin Infusions Set

N/AType 1 Diabetes

Mio Advanced infusions setNovorapidExtended wear insulin infusion (EWIS)+1 more

Steno Diabetes Center Copenhagen80 participants1 site · DenmarkCompletes Dec 2026

Compare CT.gov Full analysis →

1–15 of 234